Key Highlights

  • Cleo Diagnostics has installed three Ella immunoassay instruments at Asuragen, a CLIA-certified laboratory in the United States.
  • The clinical validation program will test approximately 1,470 samples across three study populations.
  • Testing is expected to begin within the next month, following receipt of test kits.
  • The company plans to lodge an FDA 510(k) submission in the first half of calendar 2027, subject to completing remaining validation work.

Cleo Diagnostics Limited (ASX:COV) has established the United States laboratory infrastructure needed for clinical validation of its pre-surgical ovarian cancer test, according to an announcement dated 12 November 2026. The company describes clinical validation as the final major clinical testing program in its regulatory pathway toward an FDA 510(k) submission. Testing is expected to start within the next month at Asuragen, the CLIA-certified laboratory of Bio-Techne, once test kits arrive. The step moves the company from preparation into the operational phase of its US program, although the commercial outcome depends on the data that follows.

Laboratory setup and reproducibility work

Three of Bio-Techne's Ella automated immunoassay instruments have been installed and commissioned at Asuragen, which the company says provides the infrastructure required for clinical testing of its assay. Alongside the equipment, inter-laboratory reproducibility studies are underway. These studies compare results from Cleo's Melbourne Facility with those from Asuragen, using the same Manufacturing batch, to confirm that the assay performs consistently across the two sites.

The reproducibility work matters because clinical data generated in the United States must be reliable enough to support a regulatory filing. Until those studies are complete, the company cannot yet show that results from the two laboratories align, and any variation found would need explanation before the clinical dataset can be relied upon.

How the clinical validation program is structured

The program comprises three studies involving approximately 1,470 samples. The Pivotal Clinical Performance Study uses about 600 prospectively collected blood samples from the pivotal US clinical trial, conducted across 19 sites, to assess how well the test separates benign from malignant ovarian disease in women with a suspicious ovarian mass. The Clinical Specificity Study includes around 570 samples from patients with non-ovarian benign and malignant conditions, designed to identify factors that could confound results and to inform product labelling. The Healthy Individuals Study uses roughly 300 samples from healthy women to establish the expected distribution of test scores.

The resulting data will generate sensitivity and specificity estimates within the intended clinical application. Combined with results from the company's ongoing analytical validation work, these findings will form the core evidence package for the proposed FDA submission. The company's underlying technology relies on the CXCL10 biomarker, which it says is produced at high levels in ovarian cancer and is largely absent in benign disease. The company also cites a five-year mortality rate of 51% for ovarian cancer, largely linked to late diagnosis.

Remaining milestones and timing risks

Several steps remain before the filing. Analytical validation must be completed across three independently manufactured production batches, the commercial assay algorithm must be finalised, and clinical validation must be completed, including the pivotal trial and control sample testing. Clinical data analysis and trial results will then need to be assembled into the submission. Each of these steps carries execution risk, and a delay in any of them would push back the planned first-half 2027 timetable.

The announcement does not disclose the expected results of the clinical validation program, which means the performance claims for the test remain untested in the intended population until the data are analysed. Sample sizes for the control and healthy populations are also substantial, so the timing of the analysis may depend on sample logistics and laboratory throughput. Investors will need to weigh these uncertainties alongside the progress the company has reported.

Final Word

Cleo Diagnostics has moved from the design stage to laboratory readiness for its most significant pre-submission program. The installed equipment, the defined sample structure and the reproducibility work indicate that the program is taking shape, yet the clinical performance of the test has not yet been measured in the setting the company intends to serve. The coming months will show whether testing starts on schedule and whether the reproducibility studies support the plan for a first-half 2027 submission.